- Horizon Therapeutics plc's HZNP Phase 2 trial evaluating dazodalibep for Sjögren's syndrome met its primary endpoint in the second patient population.
- Sjogren's syndrome is an immune system disorder identified by its two most common symptoms — dry eyes and a dry mouth.
- Results in the first patient population were announced in September 2022. The company says that Dazodalibep is the only medicine in development to achieve the primary endpoint in both patient populations in a Phase 2 trial.
- Related: Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share.
- This patient population is defined as patients with a European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI) score of ≥ 5 and a score of <5 on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), which measures organ involvement.
- At Day 169, dazodalibep-treated patients achieved a 1.8-point reduction in their ESSPRI scores compared to placebo-treated patients achieving a 0.53-point reduction.
- The ESSPRI is a composite endpoint that measures dryness, pain, and fatigue severity.
- The trial also achieved statistical significance in certain secondary quality-of-life measures.
- Price Action: HZNP shares are trading 0.12% lower at $112.97 on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: BiotechNewsHealth CareGeneralBriefs